GlassScriptPhysician profile
Noli A Cava
NPI 1265453435
$13,821.74
in general payments reported to CMS, 2019-2025
58 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,104 · 2020: $1,454 · 2021: $2,489 · 2022: $2,512 · 2023: $1,728 · 2024: $1,725 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,233 · Education: $30.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,232.94 |
| Education | $30.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,982.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,150.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $900.24 | 2019-2025 | |
| Boston Scientific Corporation | $646.75 | 2019-2021 | |
| Abbvie INC. | $612.80 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $611.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $561.11 | 2019-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $551.34 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $544.33 | 2021-2024 | |
| Pfizer INC. | $424.48 | 2019-2025 | |
| Mannkind Corporation | $416.58 | 2019-2022 | |
| Biotronik INC. | $398.41 | 2019-2021 | |
| Almatica Pharma LLC | $344.35 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Abbott Laboratories | $311.84 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $301.74 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noli Cava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.